Echelon Wealth Partners Thinks Indiva’s Stock is Going to Recover

In a report issued on April 20, Andrew Semple from Echelon Wealth Partners maintained a Buy rating on Indiva (NDVAFResearch Report). The company’s shares closed last Friday at $0.20, close to its 52-week low of $0.19.

According to TipRanks.com, Semple is a 4-star analyst with an average return of 12.8% and a 24.4% success rate. Semple covers the Basic Materials sector, focusing on stocks such as Ascend Wellness Holdings LLC, Green Thumb Industries, and Trulieve Cannabis.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Indiva.

See the top stocks recommended by analysts >>

Indiva’s market cap is currently $25.29M and has a P/E ratio of -1.78.

Based on the recent corporate insider activity of 25 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of NDVAF in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Indiva Ltd. engages in the construction of a medical marijuana facility. It offers dried cannabis flower, chocolate, accessories, and oil. The company was founded by Niel Marotta and Koby Smutylo on May 12, 2015 and is headquartered in Ottawa, Canada.

Read More on NDVAF:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Latest News Feed